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A n association between excessive alcohol intake and atrial arrhythmias was described about 40 years ago as “holiday heart syndrome.”1 Since then, several studies 
have shown that even low amounts of regular alcohol intake are 
independently associated with an increased risk of incident atrial 
fibrillation (AF).2–4
In contrast, little is known about the effects of alcohol intake 
on the risk of adverse events among patients with established AF.5 
These patients have a high risk of stroke.6,7 The use of oral antico-
agulation significantly decreases stroke risk,8 but a residual risk 
persists and the risk of bleeding is increased. As alcohol con-
sumption has been associated with stroke risk in non-AF popula-
tions, reduced alcohol consumption may help to further mitigate 
stroke risk in patients with AF. In addition, alcohol consumption 
may interfere with adherence to oral anticoagulation, increase 
bleeding risk and lead to more frequent falls, such that the 
effects of alcohol intake on stroke risk observed in other popula-
tions may be not be generalizable to patients with AF.9–14
For all these reasons, many physicians recommend to patients 
with established AF to fully abstain from alcohol. However, these 
RESEARCH    CPD
Alcohol consumption and risk of cardiovascular 
outcomes and bleeding in patients with 
established atrial fibrillation
Philipp Reddiess MD, Stefanie Aeschbacher PhD, Pascal Meyre MD PhD, Michael Coslovsky PhD,  
Michael Kühne MD, Nicolas Rodondi MD MAS, Oliver Baretella MD PhD, Jürg H. Beer MD, Richard Kobza MD, 
Giorgio Moschovitis MD, Marcello Di Valentino MD, Cyrill Müller MD, Fabienne Steiner MD, Leo H. Bonati MD, 
Christian Sticherling MD Stefan Osswald MD, David Conen MD MPH; for the BEAT-AF and Swiss-AF 
investigators*
n Cite as: CMAJ 2020 January 25;193:E117-23. doi: 10.1503/cmaj.200778
ABSTRACT
BACKGROUND: Little is known about the 
association between alcohol consump-
tion and risk of cardiovascular events in 
patients with established atrial fibrilla-
tion (AF). The main aim of the current 
study was to investigate the associa-
tions of regular alcohol intake with inci-
dent stroke or systemic embolism in 
patients with established AF.
METHODS: To assess the association 
between alcohol consumption and car-
diovascular events in patients with 
established AF, we combined data from 
2 comparable prospective cohort stud-
ies that followed 3852 patients with AF 
for a median of 3.0 years. Patients were 
grouped into 4 categories of daily alco-
hol intake (none, > 0 to < 1, 1 to < 2 and 
≥  2  drinks/d). The primary outcome 
was a composite of stroke and sys-
temic embolism. Secondary outcomes 
were all-cause mortality, myocardial 
infarction, hospital admission for acute 
heart failure, and a composite of major 
and clinically relevant nonmajor bleed-
ing. Associations were assessed using 
time-updated, multivariable-adjusted 
Cox proportional hazards models.
RESULTS: Mean age (± standard devia-
tion) was 71 ± 10 years (28% were women 
and 84% were on oral anticoagulants). 
We observed 136 confirmed strokes or 
systemic emboli. Compared with non-
drinkers, adjusted hazard ratios for the 
primary outcome event were 0.87, 95% 
confidence interval (CI) 0.55–1.37 for > 0 
to < 1 drinks/d; 0.70, 95% CI 0.39–1.25 for 
1 to < 2 drinks/d; and 0.96, 95% CI 0.56–
1.67 for ≥  2 drinks/d (p for linear [qua-
dratic] trend 0.71 [0.22]). There was no sig-
nificant association between alcohol 
consumption and bleeding, but there was 
a nonlinear association with heart failure 
(p for quadratic trend 0.01) and myocardial 
infarction (p for quadratic trend 0.007).
INTERPRETATION: In patients with AF, 
we did not find a significant association 
between low to moderate alcohol intake 
and risk of stroke or other cardiovascu-
lar events. Our findings do not support 
special recommendations for patients 
with established AF with regard to alco-
hol consumption. Trial registration: 
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recommendations are largely based on expert opinions, and pro-
spective data are needed to address this important gap in know-
ledge. Therefore, the main aim of our study was to investigate 
the association of regular alcohol intake with incident stroke or 
systemic embolism in patients with established AF. As secondary 
objectives, we also assessed the associations of alcohol intake 
with incident death, hospital admission for heart failure, myocar-
dial infarction and bleeding.
Methods
Setting and design
The Basel Atrial Fibrillation (BEAT-AF) and Swiss Atrial Fibrillation 
(Swiss-AF) cohort studies are prospective, observational cohort 
studies conducted in Switzerland. Between 2010 and 2014, BEAT-
AF enrolled 1553 patients with documented AF across 7 centres 
in Switzerland. BEAT-AF was initiated to assess the feasibility of a 
multicentre AF cohort study in Switzerland. The main aim of 
Swiss-AF was to explore the associations of AF with structural 
and functional brain damage. In Swiss-AF, 2415 patients with 
documented AF were enrolled between 2014 and 2017 across 
14 Swiss centres. Details on the Swiss-AF study design have been 
published previously.15,16 Inclusion criteria for both cohorts were 
a prior documentation of AF and an age of 65 years or older. Both 
cohorts enrolled a small convenience sample of patients aged 
45–64 years, to assess the effects of AF on individuals in the 
active workforce. Patients in Beat-AF could not be enrolled in 
Swiss-AF. In both cohorts, we excluded patients who were 
unable to sign informed consent, or had only short, potentially 
reversible AF episodes (e.g., after cardiac surgery or sepsis). 
Patients with an acute illness within the previous 4 weeks could 
be enrolled once the acute episode had resolved. To maximize 
the number of outcome events, we combined both cohorts for 
this analysis, given the similar eligibility criteria, study setting 
and study methodology.
From a total of 3968 patients enrolled in both studies, 
7 patients were excluded from Beat-AF as they were enrolled in 
both studies, 67 patients were excluded owing to study termina-
tion without having any follow-up information and 42  patients 
were excluded because of missing information on alcohol intake 
or covariates, such that 3852 patients remained in this analysis. 
Baseline characteristics for each cohort are shown in Appendix 1, 
Table S1, available at www.cmaj.ca/lookup/doi/10.1503/
cmaj.200778/tab-related-content.
Data collection
In both cohorts, we used identical standardized case report 
forms to collect information about personal characteristics, risk 
factors and comorbidities. A copy of the form is provided in 
Appendix 2, available at www.cmaj.ca/lookup/doi/10.1503/
cmaj.200778/tab-related-content. We calculated body mass 
index (BMI) as weight in kilograms divided by height in metres 
squared. We measured blood pressure 3 times in a supine posi-
tion and used the mean of all values in this analysis. We classified 
type of AF according to the current European guidelines, as par-
oxysmal, persistent or permanent.17 We collected information on 
health perception using a visual analogue scale (VAS), scaled 
from 0 (worst) to 100 (best). During yearly follow-up visits, we 
updated data on these characteristics, and collected information 
about adverse outcome events.
Assessment of alcohol consumption
Using the same standardized case report forms in both cohorts, 
we asked participants to indicate the average frequency of alco-
holic beverages consumed over the last 12 months, and updated 
alcohol consumption on a yearly basis. One drink was defined as 
100 mL of wine, 20 mL of liquor, or 300 mL of beer. For each type 
of alcoholic beverage, participants had to indicate the frequency 
of alcohol consumption as never or less than 1 drink per month, 
1 to 3 drinks per month, 1 drink per week, 2 to 4 drinks per week, 
5 to 6 drinks per week, 1 drink per day, 2 to 3 drinks per day, 4 to 
5 drinks per day, or 6 or more drinks per day. To be consistent 
with previous studies, we categorized the patients into 1 of the 
following prespecified categories of alcohol intake:3,18 nondrink-
ers, drinkers consuming > 0 to <  1 drinks per day, drinkers con-
suming 1 to < 2 drinks per day, and drinkers consuming ≥ 2 drinks 
per day.
Outcome events
The primary outcome was a composite of total stroke (ischemic 
or hemorrhagic) and systemic embolism. Secondary outcomes 
included a composite of major and clinically relevant nonmajor 
bleeding,19 hospital admission for acute heart failure, myocar-
dial infarction and all-cause mortality. In addition to the infor-
mation obtained from the patients during the yearly follow-up 
visits, we also screened all available hospital records for the 
presence of a possible outcome event. All reported outcome 
events were independently validated by 2 physicians using stan-
dardized definitions. In cases of disagreement, a third physician 
was consulted. Definitions of these outcomes are provided in 
Appendix 1, Table S2. Patients and assessors were unaware of 
the study question.
Statistical analysis
We stratified baseline characteristics according to alcohol con-
sumption. We calculated person-years of follow-up for all out-
comes from the date of the baseline visit to the time of first 
 outcome event of each analysis, dropout, loss to follow-up, 
death or Apr. 16, 2019.
To compare the associations between categories of alcohol 
intake and individual outcome events, we constructed time-
updated Cox proportional hazards models to take into account 
potential changes of alcohol consumption and other covariates 
over time. We adjusted all regression models for a predefined set 
of covariates. After adjusting for age and sex in a first step, we 
adjusted all models for education, hypertension, history of heart 
failure, history of diabetes, BMI, smoking status, physical activity, 
history of stroke, history of coronary heart disease, oral antico-
agu lation, history of renal failure, AF type and health perception. 
We updated all covariates over time if appropriate. All results are 
presented as hazard ratios (HRs) and 95% confidence intervals 
(CIs) across categories of alcohol intake, using the nondrinkers as 
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the reference group. We calculated p values for linear and quad-
ratic trend across categories of alcohol consumption.
We performed several sensitivity analyses. First, to assess the 
potential influence of the 2 individual cohorts, we additionally 
adjusted all multivariable models for cohort. Second, to address 
the possibility that patients with future events may reduce alco-
hol intake over time because of poor health, we re-ran the main 
analyses without updating covariates over time. Finally, we per-
formed sex-specific analyses for the associations of alcohol 
intake with all outcome events. We calculated p values for inter-
action using multiplicative interaction terms in the nonstratified 
models. We performed all statistical analyses using R (R version 
3.4.1 Vienna, Austria). Estimates are provided with 95% CIs and 
2-sided p values.
Ethics approval
The Ethikkommission Nordwest- und Zentralschweiz (EKNZ) 
approved both study protocols as the lead ethics committee. We 
obtained informed written consent from all participants.
Results
Baseline characteristics stratified by alcohol consumption are 
shown in Table 1. Of the 3852 patients, 689 (18%) were nondrinkers, 
1782 (46%) consumed > 0 to < 1 drink per day, 646 (17%) 1 to 
<  2  drinks per day, and 735 (19%) ≥ 2 drinks per day. Mean age 
(± standard deviation) was 71 ± 10 years, 28% were women and 84% 
were on anticoagulation at the time of enrolment. It was more likely 
that patients with higher alcohol intake were male, better educated, 
Table 1: Baseline characteristics according to alcohol consumption
Characteristic
Overall no. (%)*  
of patients
n = 3852
No. (%)*  
of patients who 
were nondrinkers
n = 689
No. (%)*  
of patients who 
consumed 
> 0 to < 1 drink/d
n = 1782
No. (%)*  
of patients who 
consumed 
1 to < 2 drinks/d
n = 646
No. (%)*  




Mean age ± SD, yr 71 ± 10 72 ± 10 71 ± 10 73 ± 10 72 ± 8
Female sex 1078 (28) 362 (53) 522 (29) 114 (18) 80 (11)
Ethnicity, White† 3800 (99) 671 (97) 1760 (99) 641 (99) 728 (99)
BMI, kg/m2  ± SD 27.4 ± 4.8 28.0 ± 5.7 27.4 ± 4.7 27.0 ± 4.4 27.3 ± 4.2
Current smoker 298 (8) 56 (8) 117 (7) 36 (6) 89 (12)
Regular exercise 1875 (49) 265 (39) 927 (52) 326 (51) 357 (49)
Education level‡
    Basic 456 (12) 162 (24) 171 (10) 49 (8) 74 (10)
    Middle 1897 (49) 369 (54) 899 (50) 311 (48) 318 (43)
    Advanced 1499 (39) 158 (23) 712 (40) 286 (44) 343 (47)
Atrial fibrillation type
    Paroxysmal 1899 (49) 343 (50) 911 (51) 319 (49) 326 (44)
    Persistent 1047 (27) 162 (24) 493 (28) 179 (28) 213 (29)
    Permanent 906 (24) 184 (27) 378 (21) 148 (23) 196 (27)
    AF-related symptoms§ 2550 (66) 468 (68) 1237 (70) 424 (66) 422 (57)
Health perception (VAS)¶ 72 ± 18 67 ± 20 73 ± 18 74 ± 17 72 ± 18
Medical history
    Hypertension 2645 (69) 505 (73) 1194 (67) 427 (66) 519 (71)
    Diabetes 604 (16) 153 (22) 251 (14) 87 (13) 113 (15)
    Stroke or TIA 663 (17) 127 (18) 296 (17) 123 (19) 117 (16)
    Heart failure 917 (24) 185 (27) 420 (24) 147 (23) 165 (22)
    Coronary heart disease 1031 (27) 196 (28) 465 (26) 166 (26) 204 (28)
    Renal failure 716 (19) 167 (24) 316 (18) 116 (18) 117 (16)
    Recurrent falls 259 (7) 66 (10) 109 (6) 35 (5) 49 (7)
    Oral anticoagulation 3248 (84) 576 (84) 1488 (84) 554 (86) 630 (86)
Note: BMI = body mass index, SD = standard deviation, TIA = transient ischemic attack, VAS = visual analogue scale. 
*Unless otherwise specified.
†Missing values: 8
‡Basic: ≤ 6 years (less than the current compulsory education curriculum); middle: 6 to ≤ 12 years (high school or similar); advanced: ≥ 12 years (college or university degree).
§Includes palpitations, dizziness, chest pain, effort intolerance, dyspnea, fatigue, syncope or other.
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active smokers and physically active. They also had a lower preva-
lence of diabetes, renal failure and AF-related symptoms (Table 1). 
There was very little change in the distribution of alcohol intake over 
time, in patients both with and without an incident primary event 
(Appendix 1, Figure S1). Baseline characteristics stratified by cohort 
are presented in Appendix 1, Table S1.
After a median follow-up of 3.0 years, the primary outcome of 
stroke or systemic embolism occurred in 136  patients, with an 
incidence of 1.01 per 100 person-years of follow-up. The inci-
dence across categories of increasing alcohol intake was 1.29, 
0.90, 0.90 and 1.12 per 100 person-years (Table 2). Compared 
with nondrinkers, the multivariable adjusted HRs (95% CIs) for 
Table 2: Associations between alcohol consumption and adverse clinical outcome events
Outcome events Nondrinkers
> 0 to  < 1 
drink/d
1 to < 2 
drinks/d  ≥ 2 drinks/d
p for linear 
trend
p for quadratic 
trend
Stroke or systemic embolism
Events 31 57 21 27
Person-years 2395 6321 2325 2406
Incidence per 100 person-years 1.29 0.90 0.90 1.12
Hazard ratio (95% CI)
Age and sex adjusted 1 (Ref.) 0.74 (0.47–1.16) 0.65 (0.36–1.14) 0.83 (0.48–1.43) 0.43 0.13
Multivariable adjusted* 1 (Ref.) 0.87 (0.55–1.37) 0.70 (0.39–1.25) 0.96 (0.56–1.67) 0.71 0.22
Major bleeding or clinically relevant nonmajor bleeding
Events 115 264 91 108
Person-years 2240 5984 2198 2264
Incidence per 100 person-years 5.13 4.41 4.14 4.77
Hazard ratio (95% CI)
Age and sex adjusted 1 (Ref.) 0.90 (0.72–1.12) 0.73 (0.55–0.97) 0.86 (0.65–1.13) 0.14 0.13
Multivariable adjusted* 1 (Ref.) 0.95 (0.76–1.20) 0.78 (0.59–1.05) 0.93 (0.70–1.23) 0.37 0.23
Hospital admission for heart failure
Events 98 178 43 77
Person-years 2327 6160 2279 2338
Incidence per 100 person-years 4.21 2.89 1.89 3.29
Hazard ratio (95% CI)
Age and sex adjusted 1 (Ref.) 0.75 (0.58–0.97) 0.41 (0.29–0.60) 0.75 (0.55–1.03) 0.005 < 0.001
Multivariable adjusted* 1 (Ref.) 1.00 (0.77–1.29) 0.60 (0.41–0.87) 1.07 (0.78–1.47) 0.54 0.01
All-cause mortality
Events 121 136 51 65
Person-years 2463 6419 2364 2440
Incidence per 100 person-years 4.91 2.12 2.16 2.66
Hazard ratio (95% CI)
Age and sex adjusted 1 (Ref.) 0.41 (0.32–0.53) 0.34 (0.24–0.47) 0.42 (0.31–0.58) < 0.001 < 0.001
Multivariable adjusted* 1 (Ref.) 0.61 (0.47–0.79) 0.49 (0.35–0.69) 0.63 (0.45–0.86) 0.002 0.001
Myocardial infarction
Events 35 31 12 17
Person-years 2420 6360 2345 2419
Incidence per 100 person-years 1.45 0.49 0.51 0.70
Hazard ratio (95% CI)
Age and sex adjusted 1 (Ref.) 0.34 (0.20–0.55) 0.30 (0.15–0.59) 0.42 (0.23–0.78) 0.007 0.002
Multivariable adjusted* 1 (Ref.) 0.41 (0.25–0.69) 0.39 (0.20–0.78) 0.55 (0.29–1.03) 0.07 0.007
Note: CI = confidence interval, Ref. = reference category.
*Adjusted for age, sex, education, hypertension, history of heart failure, history of diabetes, body mass index, smoking status, physical activity, history of stroke, anticoagulation, 
history of coronary heart disease, renal failure, atrial fibrillation type and health perception.
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stroke and systemic embolism were 0.87 (0.55–1.37), 0.70 (0.39–
1.25) and 0.96 (0.56–1.67) across increasing categories of alcohol 
consumption. There was no evidence for a linear or nonlinear 
trend across these categories, as shown in Table 2 and Figure 1. 
Coefficients for the other model covariates are provided in 
Appendix 1, Table S3.
Absolute and relative risks for all secondary outcomes are 
shown in Table 2 and Figure 1. We found no strong evidence for a 
linear or nonlinear association of alcohol consumption with 
bleeding. For mortality, there was evidence of a nonlinear associ-
ation (p for quadratic trend 0.001), with those drinking 1 to 
< 2  alcoholic beverages per day having the lowest risk of death. 
There was also a nonlinear association between alcohol con-
sumption and myocardial infarction (p value for quadratic trend 
0.007), and hospital admission for heart failure (p for quadratic 
trend 0.01) (Table 2 and Figure 1). The HRs (95% CIs) for all 
covariates are presented in Appendix 1, Table S3.
Additional adjustment for cohort did not change our results 
(Appendix 1, Table S4). Using baseline covariates only without 
updating over time resulted in similar findings, as shown in 
Appendix 1, Table S5. Finally, sex-specific analyses of associa-
tions between alcohol consumption and outcome events are 
shown in Appendix 1, Table S6. In addition, none of the alcohol 
intake by sex interaction terms were statistically significant.
Interpretation
In this combined cohort of patients with AF, we found no signifi-
cant association between alcohol consumption and risk of stroke 
or systemic embolism. Alcohol consumption was not associated 
D) Myocardial infarction
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Figure 1: Hazard ratios (HRs) stratified by categories of alcohol consumption: A) stroke or systemic embolism; B) major bleeding or clinically 
 relevant nonmajor bleeding; C) hospital admission for acute heart failure; D) myocardial infarction; E) all-cause mortality. Nondrinkers are the 
 reference group. All risk estimates were adjusted for age, sex, education, hypertension, history of heart failure, history of diabetes, body mass index, 
smoking status, physical activity, history of stroke or transient ischemic attack, anticoagulation, history of coronary heart disease, renal failure, 
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with an increased risk of bleeding, despite most participants 
receiving oral anticoagulation for stroke prevention. We observed 
nonlinear associations of alcohol intake with mortality, myocar-
dial infarction and hospital admissions for heart failure, similar to 
associations previously reported in general population samples.20
Patients with AF are usually older adults with multiple comor-
bidities. It is therefore reassuring that in our study, alcohol con-
sumption was not associated with an increased risk of stroke or 
systemic embolism, although a small effect cannot be excluded 
given the width of the CIs described in Table 2. Furthermore, the 
absolute difference in stroke risk between categories of alcohol 
consumption was small, ranging from 0.9 to 1.27  events per 
100 person-years.
Many of these patients need to take oral anticoagulation for 
stroke prevention and therefore have an increased risk of bleed-
ing. Alcohol consumption may cause further harm by inducing 
falls, medication errors or medication interactions. It is reassur-
ing that alcohol consumption was not associated with an 
increased risk of bleeding, with a small difference in absolute risk 
across drinking categories, although most patients were taking 
oral anticoagulation.
The associations between alcohol intake and incident cardio-
vascular events in the general population are well studied.3,11,21–23 
Many studies have found that low to moderate alcohol consump-
tion was associated with a lower risk of stroke, all-cause mortal-
ity or myocardial infarction.23–27 In our study of patients with AF, 
alcohol consumption had similar associations with these out-
come events. Our data suggest no excess risk of adverse cardio-
vascular events among patients with AF who consumed low to 
moderate amounts of alcohol. Similar recommendations with 
regard to the safety of alcohol intake as in the general population 
seem appropriate for patients with AF.
Strengths of this study include the availability of well-characterized 
patients with AF with an average follow-up of 3 years and with 
covariates updated on an annual basis. All clinical outcome data 
were validated. The amount of missing data was very low. 
Limitations
Our study has a number of potential limitations. First, although 
we controlled for the obvious potential confounders, some 
unknown residual confounding may persist and could influence 
the observed associations. Causality cannot be established in an 
observational study. For instance, nondrinkers tended to have a 
higher prevalence of several comorbidities (Table 1), raising the 
possibility of residual confounding by contraindication. Second, 
alcohol consumption was self-reported. However, studies in 
other populations have shown that the reliability of self-
reported alcohol consumption is usually good.28 Nevertheless, 
the possibility of systematic underreporting of alcohol intake 
should be considered. Third, virtually all participants in our 
study were White, and the generalizability of our results to other 
ethnic groups is unclear. Fourth, the width of the confidence 
intervals around some of the hazard ratios of association were 
quite wide. Finally, our study did not include a large number of 
heavy or binge drinkers, and our results may therefore not apply 
to these patients.
Conclusion
In this study of patients with AF, low to moderate alcohol intake 
was not associated with an increased risk of stroke and other 
cardiovascular events. Alcohol intake was not associated with an 
increased risk of bleeding. The observed associations were simi-
lar to those in previous general population studies. Therefore, 
our findings do not support special recommendations for 
patients with AF with respect to alcohol consumption.
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